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To the Editor: We applaud Walsh and colleagues’ interest in
replacing the unpalatable ammonium chloride (NH4Cl) test
of urine acidification capacity for the diagnosis of distal renal
tubular acidosis (dRTA).1 We note that their study showed
perfect concordance with the more modern fludrocortisone/
furosemide test in a group of patients previously known to
have dRTA, and in healthy volunteers.
Recurrent renal stone formers have a relatively high
incidence of an impaired capacity to acidify their urine with
reported prevalences ranging from 6 to 20%, depending on
the selection criteria employed.2 Hence, further investigation
in this group is often warranted. However, in clinical practice,
any new test must have sufficient positive and negative
predictive value if it is to be useful as a diagnostic rather than
confirmatory tool. To address this, we have performed a
similar study in 10 adult patients presenting with clinical
suspicion of dRTA and 10 healthy volunteers. All 10 patients
had recurrent nephrolithiasis and/or nephrocalcinosis; three
had a family history of nephrolithiasis. All subjects had
random urine pH45.5. All subjects underwent both
fludrocortisone/furosemide testing (1 mg 10 h pretest/40 mg
day of test) and NH4Cl testing on separate occasions at the
same time of day. All potentially confounding drugs were
stopped the week before testing.
All 10 healthy volunteers were able to acidify their urine to
pHo5.3 with both tests (Figure 1). However, while all 10
patients acidified normally with NH4Cl, with fludrocorti-
sone/furosemide only 3 of 10 reduced their urine pH too5.3
(or indeed o5.5, the pH used in the original NH4Cl report;3
Figure 1). Thus, the negative predictive value of the newer
test for disease was 100% but the positive predictive value
was very much less.
These data suggest that the fludrocortisone/furosemide
test is a useful screening tool to rule out dRTA, but failing
this test does not necessarily imply that dRTA is present. The
only difference in our protocol was the prior administration
of fludrocortisone, as in Walter et al.’s earlier report of this
test in healthy individuals, where all passed.4 With a half-life
of 18–36 h, this difference is unlikely to account for the
disparate results.
We therefore counsel caution in extrapolating Walsh’s
conclusions to the at-risk clinical population. We recom-
mend instead that in adults at least, the fludrocortisone/
furosemide test be used first, with a follow-up NH4Cl test if
acidification is not achieved.
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Figure 1 | Paired pretest and nadir urine pH values for normal controls (closed symbols) and patients with nephrolithiasis and/or
nephrocalcinosis (open symbols) subjected to NH4Cl (diamonds) and fludrocortisone/furosemide (squares) tests.
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